# US 2017/0285002 A1 · Method for reconstituting tumor with microenvironment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0285002 A1
- Document ID: US20170285002A1
- Status: Published application
- Kind: A1
- Application number: 15/461,217
- Filed: 2017-03-16
- Published: 2017-10-05
- Earliest claimed: 2016-03-16
- Assignees: Public University Corporation Yokohama City University
- Applicants: Public University Corporation Yokohama City University
- Inventors: Hideki TANIGUCHI; Yasuharu UENO; Takanori TAKEBE; Keisuke SEKINE; Ryo OKUDA
- Web page: https://patentgrep.com/patent/US20170285002A1

## CPC

- G01N 33/5011: {for testing antineoplastic activity}
- A61K 35/13: Tumour cells, irrespective of tissue of origin (tumour vaccines A61K39/00)
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- C12N 5/0068: {General culture methods using substrates (for specific animal cell type C12N5/06)}
- C12N 5/0677: {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
- C12N 5/0693: {Tumour cells; Cancer cells}
- G01N 33/5088: {of vertebrates}
- C12N 2510/00: Genetically modified cells
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

It is intended to develop a technique that can reproduce a microenvironment of cancer tissue and to construct a novel drug discovery screening system of high precision. It is also intended to provide a method for reconstituting human cancer tissue using primary human cancer cells that retain the properties of human tumor. The present invention provides a reconstituted cancer organoid reproducing a cancer microenvironment. The present invention also provides a method for preparing a cancer organoid from cancer tissue, a xenograft prepared from the cancer organoid, a method for preparing the xenograft, a method for evaluating treatment resistance of cancer, a method for evaluating invasion or metastasis of cancer, a method for evaluating recurrence of cancer, and a method for conducting prognostic prediction of cancer.

## Claims

### Claim 1

A reconstituted cancer organoid reproducing a cancer microenvironment.

### Claim 2 (depends on 1)

The cancer organoid according to claim 1, wherein the cancer microenvironment comprises cancer stroma.

### Claim 3 (depends on 1)

The cancer organoid according to claim 1, wherein the cancer organoid comprises cancer cells having the properties of epithelial cells.

### Claim 4 (depends on 1)

The cancer organoid according to claim 1 further reproducing a ductal structure.

### Claim 5

A reconstituted cancer organoid reproducing at least one selected from the group consisting of treatment resistance, invasion or metastasis, and recurrence of cancer.

### Claim 6 (depends on 5)

The cancer organoid according to claim 5, wherein the treatment resistance of cancer is at least one selected from the group consisting of drug sensitivity, radiation sensitivity, immunotherapy sensitivity, and nutrition therapy sensitivity.

### Claim 7

A reconstituted cancer organoid allowing prognostic prediction of cancer.

### Claim 8

A method for preparing a cancer organoid, comprising: digesting cancer tissue in the presence of a proteolytic enzyme and a Rho kinase inhibitor and then obtaining an aggregate of cancer cells; passaging the aggregate and then separating the cancer cells; and
coculturing the cancer cells with mesenchymal cells and vascular endothelial cells to form the cancer organoid.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the cancer organoid reproduces a cancer microenvironment.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the cancer microenvironment comprises cancer stroma.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the cancer organoid comprises cancer cells having the properties of epithelial cells.

### Claim 12 (depends on 8)

The method according to claim 8, wherein the cancer organoid further reproduces a ductal structure.

### Claim 13 (depends on 8)

The method according to claim 8, wherein the cancer organoid reproduces at least one selected from the group consisting of treatment resistance, invasion or metastasis, and recurrence of cancer.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the treatment resistance of cancer is at least one selected from the group consisting of drug sensitivity, radiation sensitivity, immunotherapy sensitivity, and nutrition therapy sensitivity.

### Claim 15 (depends on 8)

The method according to claim 8, wherein the cancer organoid allows prognostic prediction of cancer.

### Claim 16

A method for preparing a xenograft reproducing a cancer microenvironment, comprising transplanting a nonhuman animal with a reconstituted cancer organoid reproducing a cancer microenvironment.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the cancer microenvironment of the xenograft comprises cancer stroma.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the reconstituted cancer organoid comprises cancer cells having the properties of epithelial cells.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the reconstituted cancer organoid further reproduces a ductal structure.

### Claim 20 (depends on 16)

The method according to claim 16, wherein the xenograft further reproduces a ductal structure.

### Claim 21 (depends on 16)

The method according to claim 16, wherein the xenograft reproduces at least one selected from the group consisting of treatment resistance, invasion or metastasis, and recurrence of cancer.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the treatment resistance of cancer is at least one selected from the group consisting of drug sensitivity, radiation sensitivity, immunotherapy sensitivity, and nutrition therapy sensitivity.

### Claim 23 (depends on 16)

The method according to claim 16, wherein the xenograft allows prognostic prediction of cancer.

### Claim 24

A xenograft reproducing a cancer microenvironment, the xenograft being obtained by transplanting a nonhuman animal with a reconstituted cancer organoid reproducing a cancer microenvironment.

### Claim 25 (depends on 24)

The xenograft according to claim 24, wherein the cancer microenvironment of the xenograft comprises cancer stroma.

### Claim 26 (depends on 24)

The xenograft according to claim 24, wherein the xenograft comprises cancer cells having the properties of epithelial cells.

### Claim 27 (depends on 24)

The xenograft according to claim 24 further reproducing a ductal structure.

### Claim 28

A reconstituted cancer organoid-derived xenograft reproducing at least one selected from the group consisting of treatment resistance, invasion or metastasis, and recurrence of cancer.

### Claim 29 (depends on 28)

The xenograft according to claim 28, wherein the treatment resistance of cancer is at least one selected from the group consisting of drug sensitivity, radiation sensitivity, immunotherapy sensitivity, and nutrition therapy sensitivity.

### Claim 30

A reconstituted cancer organoid-derived xenograft allowing prognostic prediction of cancer.

### Claim 31

A reconstituted cancer organoid-derived xenograft reproducing expression of a drug transporter.

### Claim 32

A reconstituted cancer organoid-derived xenograft having tumor vessels.

### Claim 33

A reconstituted cancer organoid-derived xenograft reproducing drug leakage characteristic of tumor vessels.

### Claim 34 (depends on 1)

A method for evaluating treatment resistance of cancer using a cancer organoid according to claim 1.

### Claim 35 (depends on 1)

A method for evaluating invasion or metastasis of cancer using a cancer organoid according to claim 1.

### Claim 36 (depends on 1)

A method for evaluating recurrence of cancer using a cancer organoid according to claim 1.

### Claim 37 (depends on 1)

A method for conducting prognostic prediction of cancer using a cancer organoid according to claim 1.

### Claim 38 (depends on 24)

A nonhuman animal carrying a xenograft according to claim 24.
